BioNTech SE Announces Positive Phase‑3 Outcomes for Trastuzumab Pamirtecan

BioNTech SE, a German biotechnology company headquartered in Mainz, disclosed that its global Phase‑3 clinical trial, DYNASTY‑Breast02 (NCT06018337), has successfully met its primary endpoint. The study evaluated trastuzumab pamirtecan (BNT323/DB‑1303), a novel antibody‑drug conjugate, in comparison with investigator‑chosen chemotherapy among chemotherapy‑naïve patients with hormone‑receptor‑positive (HR⁺), HER2‑low metastatic breast cancer.

Key Findings

  • Progression‑free survival (PFS): Trastuzumab pamirtecan demonstrated a statistically significant, albeit modest, improvement in PFS relative to chemotherapy.
  • Patient population: The trial enrolled patients who had not previously received chemotherapy, focusing on HR⁺/HER2‑low metastatic disease.
  • Global partnership: The results were achieved in collaboration with DualityBiologics (Suzhou), underscoring the joint effort to bring targeted therapies to unmet medical needs.

The announcement was made simultaneously in Mainz, Germany, and Shanghai, China, reflecting the company’s international footprint.

BioNTech SE and Bristol‑Myers Squibb Present Phase‑2 Data for Pumitamig in Advanced NSCLC

In a related development, BioNTech SE and Bristol‑Myers Squibb (BMS) reported encouraging data from a global Phase‑2 trial assessing pumitamig in combination with docetaxel for patients with advanced non‑small cell lung cancer (NSCLC) who had progressed after immunotherapy plus chemotherapy.

Trial Highlights

  • Objective response rate (ORR): A confirmed ORR of 36.7 % was observed across both squamous and non‑squamous NSCLC subtypes, spanning various PD‑L1 expression levels.
  • Progression‑free survival (PFS): The median PFS was 6.9 months, exceeding the typical <4 months seen with standard docetaxel in this setting.
  • Unmet need: The data address a significant gap for patients who have progressed on immunotherapy‑containing regimens, for whom current options yield limited survival benefit.

These findings were published in the same day’s releases from Finanznachrichten and GlobeNewswire, indicating a coordinated disclosure strategy.

Market Context and Company Profile

BioNTech SE, listed on the Xetra exchange in Germany, trades in euros and recorded a closing price of 78.75 EUR on 22 October 2026. With a market capitalization of approximately 22.93 billion EUR, the company has positioned itself as a leading developer of biotechnological solutions targeting oncology. Its Price‑to‑Earnings ratio of ‑12.52 reflects the early‑stage nature of its product pipeline and the substantial R&D investments required in this sector.

The company’s recent achievements reinforce its strategy of partnering with other biopharmaceutical leaders—most notably DualityBiologics and Bristol‑Myers Squibb—to accelerate the clinical development of promising antibody‑drug conjugates and small‑molecule therapies.

The information above is derived exclusively from the provided financial news excerpts and the fundamental data on BioNTech SE.